Cover Image

CL572, a potent agonist of Toll-like receptor 2/7, as a novel latency-reversing agent

Saved in:

Bibliographic Details
Main Authors:	A. Macedo (Author), C.M. Assis (Author), C.L. Novis (Author), A. Spivak (Author), V. Planelles (Author), A. Bosque (Author)
Format:	Book
Published:	Elsevier, 2015-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Ingenol derivatives are potent reactivators of latent HIV
by: V. Planelles, et al.
Published: (2015)

Direct and indirect effects of synthetic dual TLR-2 and TLR-7 agonists (Dual TLR-2/7) on latent HIV
by: A.B. Macedo, et al.
Published: (2017)

Influence of sex as an intrinsic biological variable in a primary cell model of HIV latency
by: A.B. Macedo, et al.
Published: (2017)

Optimisation of Smac mimetics as HIV-1 latency reversing agents
by: L. Pache, et al.
Published: (2019)

Cleavage and polyadenylation specific factor 6 is required for HIV latency reversal
by: Y. Zheng, et al.
Published: (2019)

SMAC mimetics are potent latency reversal agents with single agent and combination activity ex vivo
by: R.M. Dunham, et al.
Published: (2017)

Shining the RNA-Seq microscope on models of HIV latency
by: C.H. Woelk, et al.
Published: (2015)

23 Understanding the effects of latency reversing agents on HIV RNA splicing: implications for latency reversal
by: T.M. Mota, et al.
Published: (2016)

In vitro analysis of different PKC agonists: latency reversal, T-cell activation, cytokine production and isoform selectivity
by: R. Barnard, et al.
Published: (2015)

24 Thalidomide reverses latency of HIV-1 provirus
by: S. Samer, et al.
Published: (2016)

Triazol-1-ol analogues as novel therapeutic leads towards reactivating and eradicating latent HIV-1 by manipulating SUMOylation of STAT5
by: A. Bosque, et al.
Published: (2015)

Toll-like receptor agonists as cancer vaccine adjuvants
by: Donghwan Jeon, et al.
Published: (2024)

HIV latency reversal using designed PKC modulators
by: M.D. Marsden, et al.
Published: (2017)

Combinatorial latency reversal activity of inhibitor of apoptosis antagonists with mechanistically distinct classes of HIV latency reversal agents
by: Shane D. Falcinelli, et al.
Published: (2019)

Approaches to discover latency-reversing agents
Published: (2015)

Diverse interferons restrict HIV-1 Infection in macrophages through activation of SAMHD1
by: M. Szaniawski, et al.
Published: (2017)

Anti-tumor Activity of Toll-Like Receptor 7 Agonists
by: Huju Chi, et al.
Published: (2017)

The Role of Toll-like Receptor Agonists and Their Nanomedicines for Tumor Immunotherapy
by: Lingling Huang, et al.
Published: (2022)

PP 1.10 - 00069 Isotretinoin enhances IL-15 mediated HIV latency reversal and reduces the inducible latent reservoir
by: J. Howard, et al.
Published: (2022)

OP 8.2 - 00033 Interleukin-2 administration is a potent latency reversal agent in people with treated HIV infection
by: M. Freeman, et al.
Published: (2022)

OP 1.7 - 00194 Potent latency reversal enables in-depth transcriptomic analysis of the translation-competent HIV-1 reservoir
by: M. Pardons, et al.
Published: (2022)

The CCR5-agonist maraviroc reverses HIV latency, results from ex vivo studies and a randomized placebo controlled clinical trial
by: J. Symons, et al.
Published: (2017)

Transcriptomal signatures of vaccine adjuvants and accessory immunostimulation of sentinel cells by toll-like receptor 2/6 agonists
by: Alex C. D. Salyer, et al.
Published: (2018)

Bioactive Compounds from <i>Euphorbia usambarica</i> Pax. with HIV-1 Latency Reversal Activity
by: Yu-Chi Tsai, et al.
Published: (2021)

Toll-like receptor (TLRs) agonists and antagonists for COVID-19 treatments
by: Zhi-Mei Liu, et al.
Published: (2022)

Role of mitochondrial antiviral signaling protein in reactivation of latent HIV-1 in CD4+ T cells
by: C.L. Novis, et al.
Published: (2017)

The Mirror of Literature, Amusement, and Instruction. Volume 20, No. 572, October 20, 1832
by: Various

Identification of a promising new class of latency reversing agents
by: A. Gramatica, et al.
Published: (2017)

Evaluation of HIV latency reversal using designed PKC modulators in humanized BLT mice
by: M.D. Marsden, et al.
Published: (2015)

Integration site-independent enhancement of latency reversal by HIV-1 Nef
by: X.T. Kuang, et al.
Published: (2017)

Co-culture of T-cells with dendritic cells facilitates HIV latency in proliferating CD4+ T-cells: implications for the establishment and reversal of latency
by: N. Kumar, et al.
Published: (2015)

The contribution of memory CD4+ T cell subset phenotype to latency reversal efficiency
by: D.A. Kulpa, et al.
Published: (2017)

Novel use of alprazolam as a potential HIV-1 latency reversing agent
by: W. Elbezanti, et al.
Published: (2017)

36 Dose-dependent effects of HDACi on T cell activation and HIV latency reversal
by: X.T. Kuang, et al.
Published: (2016)

Synergistic HIV latency reversal from an in vitro screen of epigenetic and kinase inhibitors
by: D. Irlbeck, et al.
Published: (2017)

Insights into mechanisms of HIV reactivation from latency using RNA-Seq gene expression profiling in CD4+ T cells and their maturation subsets following treatment with latency reversing agents.
by: N. Beliakova-Bethell, et al.
Published: (2017)

38 Small molecule inhibitors of BAF; a new family of compounds in HIV-1 latency reversal
by: E. De Crignis, et al.
Published: (2016)

Utilising genetic barcodes to understand the role of silent integration in HIV latency
by: E. Larragoite, et al.
Published: (2019)

PP 1.33 - 00167 Integrated single-cell multi-omic profiling of HIV latency reversal
by: A. Manickam, et al.
Published: (2022)

Engineering Therapeutic Strategies in Cancer Immunotherapy via Exogenous Delivery of Toll-like Receptor Agonists
by: Sehwan Jeong, et al.
Published: (2021)